For the estimated 3.4 million people in the United States with Alzheimer’s disease (AD), approved pharmacotherapy is limited to four procognitive...
The Alzheimer’s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide...
DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Alzheimer’s dise...
Given the seemingly constant failure of emerging disease-modifying therapies (DMTs) in Alzheimer's disease (AD) that target the amyloid cascade...
Over the past two decades, in response to mounting failures, clinical trials of disease-modifying therapies (DMTs) in Alzheimer’s disease (
No novel pharmacotherapeutics have entered the AD market in more than 15 years, despite a perennially full pipeline. However, the potential launches...
Alongside putative disease-modifying therapies, the late-phase pipeline in Alzheimer’s disease (AD) features several therapies for the treatment...
DRG Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of k...
For the estimated 3.4 million people in the United States who suffer from Alzheimer’s disease (AD), approved pharmacotherapy is limited to four...
The Alzheimer’s disease (AD) market today comprises a handful of symptomatic options that offer only modest efficacy of limited duration, leaving...
For the estimated 3.4 million people in the United States who suffer from Alzheimer’s disease (AD), approved therapy is limited to four procognitive...
DRG Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of k...
Alzheimer’s disease (AD) is a chronic neurodegenerative condition widely recognized as a global health crisis; as the general population ages and
The market for Alzheimer’s disease (AD) pharmacotherapies represents an enormous commercial opportunity driven by considerable unmet...
There is increased industry focus on the behavioral symptoms of Alzheimer’s disease (AD), including agitation—and with good reason. Agitation...
For the estimated 3 million people in the United States who have Alzheimer’s disease (AD), approved treatment is limited to five procognitive...
Although the Alzheimer’s disease (AD) treatment paradigm is stable and most current treatments in the United States are generically available,...
The market for Alzheimer’s disease (AD) pharmacotherapies offers enormous commercial opportunity driven by considerable unmet need and looming...
Get content updates to your inbox
Subscribe